SAN MATEO, Calif. and CAMBRIDGE, Mass., Could 22, 2024 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), an organization devoted to growing small molecule therapeutics that deal with cancers and different ailments pushed by deregulated transcription, as we speak introduced that the corporate would take part in three upcoming healthcare conferences and occasions. Norbert Bischofberger, Ph.D., president and chief govt officer, will signify the corporate at these occasions.
- Could twenty eighth, 2024, Dr. Bischofberger will take part in a digital fireplace chat at 2:00 p.m. ET/11:00 a.m. PT on the TD Cowen’s fifth Annual Oncology Innovation Summit: Insights for ASCO and EHA.
- June fifth, 2024, Dr. Bischofberger will current a company overview at 1:30 p.m. ET/10:30 a.m. PT throughout the Jefferies World Healthcare Convention in New York, NY and host investor conferences the identical day.
- June 11th, 2024, Dr. Bischofberger will take part in a hearth chat on the Goldman Sachs 45th Annual World Healthcare Convention in Miami, FL at 10:40 a.m. ET/ 7:40 a.m. PT and host investor conferences the identical day.
A stay audio webcast of the occasions will likely be obtainable on the Buyers and Media part of the Kronos Bio web site at https://ir.kronosbio.com/events-presentations. Replays of the webcasts will likely be obtainable within the days following the occasions.
About Kronos Bio, Inc.
Kronos Bio, Inc. is a clinical-stage firm devoted to growing small molecule therapeutics that deal with deregulated transcription, an indicator of most cancers and different ailments. Our proprietary discovery engine decodes complicated transcription issue (TF) regulatory networks to determine druggable cofactors. We display for and optimize small molecules that concentrate on these cofactors in a tumor-specific context. These efforts have yielded a preclinical pipeline together with two internally developed drug candidates. KB-0742 targets CDK9 to handle MYC deregulation in stable tumors and KB-9558 targets p300 to handle IRF4 dependence in a number of myeloma.
Kronos Bio is predicated in San Mateo, Calif., and has a analysis facility in Cambridge, Mass. For extra data, go to https://www.kronosbio.com/ or comply with the Firm on LinkedIn.
Firm Contact:
Margaux Bennett
Vice President, Company Improvement and Investor Relations, Kronos Bio
650-781-5026
mbennett@kronosbio.com